Related Experiment Videos
Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute
Je-Hwan Lee1, Seong-Jun Choi, Jung-Hee Lee
1Department of Internal Medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, South Korea. jhlee@amc.seoul.kr
Abstract:
For refractory and early relapsed AML, this prospective phase II clinical trial evaluated a salvage chemotherapy regimen, which was consisted of continuous infusion intermediate-dose cytarabine (1g/m(2)/day, 24h i.v. infusion x 5), mitoxantrone (12 mg/m(2)/day x 3), and etoposide (150 mg/m(2)/day x 3). We treated 33 patients and 17 (51.5%) achieved CR with a median duration of 117 days. Median overall survival was 219 days. Our results suggest that continuous infusion intermediate-dose cytarabine, together with mitoxantrone and etoposide, may induce CR in a significant proportion of patients with refractory or early relapsed AML, although remission duration was short.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...